# Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab

> **NCT01022086** · — · UNKNOWN · sponsor: **Unity Health Toronto** · enrollment: 50 (estimated)

## Conditions studied

- Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)

## Interventions

- **PROCEDURE:** Cardiac MRI
- **BIOLOGICAL:** Biomarker Testing

## Key facts

- **NCT ID:** NCT01022086
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-11
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022086, "Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01022086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*